ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $77.00.

Several equities analysts recently issued reports on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Truist Financial restated a "hold" rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Raymond James upped their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research note on Wednesday, September 18th. HC Wainwright reissued a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Finally, Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday. They set an "overweight" rating and a $68.00 price objective for the company.

Insiders Place Their Bets

In other news, COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total value of $900,472.12. Following the transaction, the chief operating officer now directly owns 635,363 shares of the company's stock, valued at $40,129,527.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 25,757 shares of company stock worth $1,626,762 over the last three months. 12.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in ANI Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company's stock worth $90,314,000 after acquiring an additional 17,460 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 3.5% in the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock valued at $40,132,000 after purchasing an additional 21,053 shares during the period. Millennium Management LLC grew its holdings in ANI Pharmaceuticals by 1,005.8% during the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock valued at $14,651,000 after purchasing an additional 209,272 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its stake in ANI Pharmaceuticals by 1.5% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 195,743 shares of the specialty pharmaceutical company's stock worth $12,465,000 after buying an additional 2,986 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in ANI Pharmaceuticals by 15.4% in the 2nd quarter. Renaissance Technologies LLC now owns 156,802 shares of the specialty pharmaceutical company's stock worth $9,985,000 after buying an additional 20,900 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded up $2.04 during mid-day trading on Friday, reaching $57.14. 114,560 shares of the company's stock were exchanged, compared to its average volume of 213,570. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 35.71 and a beta of 0.71. The company has a 50-day simple moving average of $59.43 and a two-hundred day simple moving average of $62.62.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. During the same period in the prior year, the business earned $1.06 earnings per share. The business's revenue was up 18.5% on a year-over-year basis. On average, sell-side analysts predict that ANI Pharmaceuticals will post 3.58 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.